Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Phase 2, two cohort trial evaluating the addition of ublituximab and umbralisib on the rate of minimal residual disease (MRD) negativity in participants with Chronic Lymphocytic Leukemia (CLL), who are currently on treatment with ibrutinib, alacabrutinib or venetoclax.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04016805.

Trial PhasePhase II

Trial Typetreatment

Lead OrganizationTG Therapeutics Inc

• Primary IDUTX-TGR-208
• Secondary IDsNCI-2019-06447
• ClinicalTrials.gov IDNCT04016805